What is the recommended treatment for moderate to severe aortic stenosis?

Treatment of Moderate to Severe Aortic Stenosis

For symptomatic severe aortic stenosis, aortic valve replacement (either surgical AVR or TAVR) is the definitive treatment and should be performed promptly to prevent mortality, which reaches 50% at 1 year without intervention 1, 2.

Treatment Algorithm Based on Severity and Symptoms

Severe Aortic Stenosis (Symptomatic)

Intervention is mandatory - this is a Class I recommendation 1:

• Symptoms to identify: exertional dyspnea, heart failure symptoms, angina, syncope, or presyncope
• Mortality without treatment: 50% at 1 year, average survival 2-3 years 3, 4
• Treatment restores normal life expectancy when performed appropriately 4

Choice between SAVR vs TAVR - based on age and surgical risk 1, 4:

• Age ≤65 years: SAVR is preferred
• Age 66-79 years: Either SAVR or TAVR is appropriate
• Age ≥80 years OR surgical mortality ≥8%: TAVR is preferred
• Prohibitive surgical risk (≥50% mortality at 30 days, frailty, porcelain aorta, prior radiation, severe hepatic/pulmonary disease): TAVR is recommended 1

Moderate Aortic Stenosis

No intervention is recommended for isolated moderate AS 1. However, there is an important exception:

• If undergoing CABG, aortic surgery, or other valve surgery: Surgical AVR for symptomatic moderate AS is reasonable (Class IIa) 1
• Surveillance: Every 1-2 years with echocardiography 5, 4
• Medical management: Control blood pressure and cardiovascular risk factors; statins do NOT prevent AS progression 1

Critical caveat: Moderate AS carries significant mortality risk - 33.5% at 4 years untreated 6. Despite this, current guidelines do not support intervention for isolated moderate AS, even with LV dysfunction 5, 7.

Severe Aortic Stenosis (Asymptomatic)

Generally watchful waiting, but intervention is appropriate in specific scenarios 2:

Intervention is appropriate when:

• LVEF <50% (Class I recommendation) 1, 2
• Positive exercise stress test (effectively makes patient "symptomatic") 2
• Extremely severe AS: valve area ≤0.6 cm², mean gradient ≥50 mmHg, or velocity ≥5 m/s (Class IIb) 1
• Undergoing other cardiac surgery (Class I) 1, 2
• Rapid progression: velocity increase >0.3 m/s per year 8

Surveillance intervals for asymptomatic severe AS: Every 6-12 months 4, 9

Special Populations

Low-Flow Low-Gradient AS with Reduced LVEF

Must distinguish true-severe from pseudo-severe AS 8:

• Perform dobutamine stress echocardiography to assess flow reserve
• If true-severe AS confirmed: Intervention is appropriate (Class I) 8
• If pseudo-severe AS (no flow reserve, cardiomyopathy): Medical therapy for underlying cardiomyopathy 1

Patients Requiring Noncardiac Surgery

• Symptomatic severe AS + elective noncardiac surgery: AVR before noncardiac surgery is appropriate 2
• Asymptomatic or urgent surgery: May proceed with careful monitoring; balloon valvuloplasty may be appropriate as bridge 2

Treatments to AVOID

Medical therapy has NO role in symptomatic severe AS 1:

• Diuretics, vasodilators, and positive inotropes should be avoided in patients awaiting surgery due to risk of hemodynamic destabilization 1
• Statins do NOT prevent AS progression 1

Balloon aortic valvuloplasty is only reasonable for:

• Palliation when AVR cannot be performed due to comorbidities (Class IIb) 1
• Bridge to AVR (Class IIb) 1
• NOT appropriate for definitive treatment

When NOT to Intervene

Medical management is appropriate when 2:

• Life expectancy <1 year from comorbidities
• Moderate to severe dementia
• Overall health status influenced more by comorbidities than AS
• Pseudo-severe AS without flow reserve

Critical Pitfalls

1. Undertreatment of severe AS: Only 60.7% of patients with severe AS receive treatment at 4 years, despite 44.9% mortality 6
2. Delayed referral: Symptomatic patients should be treated urgently - mortality begins immediately after symptom onset 3, 4
3. Misclassifying symptomatic status: Exercise testing can unmask symptoms in "asymptomatic" patients 2
4. Ignoring moderate AS mortality: 33.5% 4-year mortality, yet treatment rates are only 11.4% 6

Essential Team-Based Approach

All decisions require multidisciplinary Heart Valve Team evaluation 1, 10:

• Interventional cardiologist
• Cardiac surgeon
• Imaging specialist
• Heart failure specialist when LVEF reduced
• Anesthesiologist for high-risk cases

This team-based approach is foundational for TAVR and increasingly important for all AS management decisions 1, 2.